Connor Clark & Lunn Investment Management Ltd. Sells 18,530 Shares of Harrow, Inc. (NASDAQ:HROW)

Connor Clark & Lunn Investment Management Ltd. trimmed its holdings in shares of Harrow, Inc. (NASDAQ:HROW) by 14.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 111,894 shares of the company’s stock after selling 18,530 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.31% of Harrow worth $3,754,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. Quest Partners LLC bought a new stake in shares of Harrow during the 3rd quarter valued at $29,000. AlphaQuest LLC grew its stake in shares of Harrow by 452.8% during the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company’s stock worth $118,000 after purchasing an additional 2,889 shares during the period. Huntington National Bank bought a new stake in Harrow in the third quarter valued at about $164,000. Virtu Financial LLC acquired a new position in Harrow in the third quarter valued at about $271,000. Finally, Principal Financial Group Inc. bought a new position in Harrow during the third quarter worth about $329,000. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Stock Up 1.3 %

NASDAQ:HROW opened at $23.32 on Tuesday. Harrow, Inc. has a 1 year low of $9.30 and a 1 year high of $59.23. The stock has a 50-day moving average price of $30.19 and a two-hundred day moving average price of $38.73. The stock has a market cap of $830.54 million, a price-to-earnings ratio of -24.81 and a beta of 0.69. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23.

Wall Street Analysts Forecast Growth

HROW has been the subject of a number of recent analyst reports. HC Wainwright started coverage on Harrow in a research note on Thursday, February 6th. They issued a “buy” rating and a $57.00 price target for the company. B. Riley decreased their price objective on shares of Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a report on Wednesday, December 4th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.